SEC Form 4 · accession 0001093557-15-000055
DEXCOM INC · DXCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Lister
Officer — Sr. VP, General Counsel
Period of report
Mar 8, 2015
Accepted (ET)
Mar 10, 2015 · 8:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001093557
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 8, 2015 | A | 37,500 | $0.001 | A | 147,518 | D | |
| Common Stock | Mar 9, 2015 | M | 5,039 | $8.85 | A | 152,557 | D | |
| Common StockF3,F4,F2 | Mar 9, 2015 | S | 5,039 | $58.7728 | D | 147,518 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy) | $8.85 | Mar 9, 2015 | M | 5,039 | D | Jan 14, 2009 | Jan 14, 2018 | Common Stock | 5,039 | 7,435 | D |
Explanation of responses
- F1Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.
- F2Included in this number are 98,333 unvested restricted stock units 37,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018, 43,333 of which were granted on March 8, 2014 and shall vest through March 8, 2017, and 17,500 of which were granted on March 11, 2013 and shall vest through March 11, 2016.
- F3On December 5, 2014, Mr. Lister adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Lister. The shares set forth above were sold pursuant to the 10b5-1 Plan.
- F4This transaction was executed in multiple trades at prices ranging from $58.48 to $59.31. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.